COVID-19 Vaccine Does Not Increase CV Event Risk in Those With Existing Disease
Findings show safety of BNT162b2 or CoronaVac vaccines in patients with cardiovascular disease
Findings show safety of BNT162b2 or CoronaVac vaccines in patients with cardiovascular disease
Larger increases in coverage seen among boys than girls, with narrowing of coverage gap
Announcement follows similar ones issued from the United Kingdom and Canada
87 percent of 397 children hospitalized during omicron predominance unvaccinated; 34 percent of unvaccinated children were Black
Vaccine effectiveness was 87.8 and 89.1% against documented and symptomatic infection, respectively
Moderna vaccine is the second COVID-19 vaccine to receive full approval from both the FDA and CDC
Vaccine uses mRNA technology to deliver HIV-specific antigens that could trigger an immune response against the virus
Chances of hospitalization for COVID-19 more than 40 times higher for those who are unvaccinated than for those with full vaccination and booster
During a season predominated by 2 vaccine-mismatched viruses, vaccination was estimated to reduce the risk of life-threatening influenza illness by 75%.
Reduction in transmission of SARS-CoV-2 associated with COVID-19 vaccination smaller for delta variant versus alpha variant